Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials

Table 1 Participants, intervention, comparison and outcome for the UCL MS-SMART and UCL MS-STAT2 clinical trial cohorts

	UCL MS-SMART	UCL MS-STAT2
Participants:	176 people with SPMS	315 people with SPMS
Age (years)	55 (34 to 65)	55 (32 to 65)
EDSS	6.0 (4.0 to 6.5)	6.0 (4.0 to 6.5)
Intervention	Fluoxetine, Riluzole or Amiloride	Simvastatin
Comparison (over encapsulated)	Placebo	Placebo
Outcome	Percentage whole brain volume change	Time to confirmed disability progression on EDSS

Characteristics of the MS-SMART and MS-STAT2 trial populations at the UCL site included in this analysis. Age and EDSS are presented as median (range)
UCL University College London, SPMS secondary progressive multiple sclerosis, EDSS expanded disability status scale

ISSN: 1745-6215